| Alzheimer Disease |
1 |
1 |
| Aducanumab |
0 |
0.99 |
| Food and Drug Administration (FDA) |
0 |
0.98 |
| Brain |
0 |
0.2 |
| Clinical Research |
0 |
0.2 |
| Mild Cognitive Impairment |
0 |
0.2 |
| Scan |
0 |
0.2 |
| Edema |
0 |
0.13 |
| Grant |
0 |
0.13 |
| Hospital |
0 |
0.13 |
| Memory |
0 |
0.13 |
| Preventive Screening |
0 |
0.13 |
| Cardiovascular Risk Management |
0 |
0.12 |
| Cerebrovascular Accident |
0 |
0.12 |
| Headache |
0 |
0.12 |
| Lipids Management |
0 |
0.12 |
| Cognitive Impairment |
0 |
0.09 |
| Geriatric Psychiatry |
0 |
0.09 |
| Apolipoproteins |
0 |
0.07 |
| Dizziness |
0 |
0.07 |
| Geriatrics |
0 |
0.07 |
| Hemorrhage |
0 |
0.07 |
| Impairment |
0 |
0.07 |
| Rhode Island |
0 |
0.07 |
| Seizure |
0 |
0.07 |